Two-Drug Combination for Treating Tuberculosis

  • Author: Natalia Ortuzar
  • Published: 28 March 2012
  • Copyright: Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim
  • Source / Publisher: 243rd American Chemical Society National Meeting and Exposition
thumbnail image: Two-Drug Combination for Treating Tuberculosis

Tuberculosis (TB) is a global health concern, with approximately one third of the world's population infected with Mycobacterium tuberculosis (Mtb), the bacterium that causes TB. Drug resistance is an increasing problem, with emergent Mtb strains (XDR-TB) that are extremely resistant to currently available antibiotics.

Professor John Blanchard and researchers at the Albert Einstein College of Medicine, New York, USA, have found new hope for the fight against TB in the form of two existing drugs already approved for clinical use: clavulanate and meropenem. When administered together, these could offer a cure for even XDR-TB.


Clavulanate, a β-lactamase inhibitor, works in conjunction with the ultra-broad-spectrum injectable β-lactam antibiotic, meropenem, to prevent Mtb's ability to break down the antibiotic, thus allowing the drug time to act. Although the evidence is currently anecdotal, with just one case reported by a doctor in Belgium, Blanchard believes that clinical evaluation of the combined off-label use of clavulanate and meropenem will reveal the combination to be a new weapon in the fight against TB. Professor Blanchard reported his findings at the 243rd American Chemical Society National Meeting and Exposition in San Diego, CA, USA, this week.



Other news from the ACS Meeting:

Article Views: 2300

Sign in Area

Please sign in below

Additional Sign In options

Please note that to comment on an article you must be registered and logged in.
Registration is for free, you may already be registered to receive, e.g., the newsletter. When you register on this website, please ensure you view our terms and conditions. All comments are subject to moderation.

Article Comments - To add a comment please sign in

Bookmark and Share

If you would like to reuse any content, in print or online, from ChemistryViews.org, please contact us first for permission. more


CONNECT:

ChemistryViews.org on Facebook

ChemistryViews.org on Twitter ChemistryViews.org on YouTube ChemistryViews.org on LinkedIn Sign up for our free newsletter


A product of ChemPubSoc Europe (16 European Chemical Societies)and Wiley-VCH